Last updated: March 28, 2026
What is NDC 00143-9005?
NDC 00143-9005 refers to a specific formulation of the EpiPen, a brand of epinephrine auto-injector used for emergency treatment of severe allergic reactions (anaphylaxis). This product is produced by Mylan (now part of Viatris). The formulation is the original EpiPen (epinephrine injection, 0.3 mg) designed for adult use.
Market Size and Demand Dynamics
Historical Context and Market Drivers
-
Prevalence of Allergic Conditions: An estimated 32 million Americans suffer from food allergies, with a rapid increase over the last decade (American College of Allergy, Asthma & Immunology, 2021).
-
Regulatory Changes: The FDA liberalized access to epinephrine auto-injectors, enabling easier purchase without prescriptions in many states, broadening consumer base (FDA, 2019).
-
Product Competition: New competitors entered following the expiration of the original patent in 2017, notably the authorized generic of the EpiPen and alternative devices like Auvi-Q and Symjepi.
Market Size
-
The global allergy immunotherapy market, in which EpiPen holds a significant share, was valued at approximately USD 4.7 billion in 2021, with auto-injectors making up around 60% of sales (Grand View Research, 2022).
-
The US auto-injector market is projected to grow at a CAGR of 6% from 2022 to 2030, driven by allergy prevalence and insurance coverage expansion.
Key Market Players
| Company |
Product Name |
Market Share |
Notes |
| Viatris (Mylan) |
EpiPen (NDC 00143-9005) |
Largest |
Dominates market; faced pricing scrutiny |
| Kaléo Pharmaceuticals |
Auvi-Q |
Second |
Less expensive alternative, preferred by some providers |
| TVAX Pharmaceuticals |
Symjepi |
Emerging |
Single-dose, pre-filled syringe, targeted to cost-sensitive segments |
Price Dynamics
Historical Pricing Trends
- 2010–2016: The EpiPen was priced at approximately USD 100 for a two-pack.
- 2016–2017: Significant price hikes resulted in a retail price reaching USD 608 for a two-pack in 2016.
- Post-Generic Entry (2018): The price declined slightly but remained above USD 300 for a two-pack.
Current Price Range (as of 2023)
| Product Type |
Average Retail Price |
Notes |
| EpiPen (Brand) |
USD 300–350 |
Two-pack, after insurance |
| Authorized Generic |
USD 250–300 |
Similar formulation, lower price |
| Auvi-Q (Brand) |
USD 250–350 |
Variation in pricing based on supplier |
| Symjepi (Generic) |
USD 120–180 |
Single-dose syringe, generally less expensive |
Price Influencing Factors
- Insurance Coverage: Many insurers place EpiPen on formularies, reducing out-of-pocket costs.
- Copay Assistance: Mylan/Viatris offers coupons reducing prices to USD 0–25 for insured patients.
- Market Competition: Entry of generics and alternative devices has capped price inflation since 2018, but brand premiums remain significant.
Future Price Projections
Short-term (2023–2025)
- Price stabilization is expected, driven by patent expirations and increased generic availability.
- The average retail price for EpiPen and authorized generics is projected to hover around USD 250–300 for a two-pack.
- Insurance and patient assistance programs will continue to influence actual patient expenditure.
Medium-term (2025–2030)
- Market penetration of lower-cost alternatives could reduce the median price of auto-injectors by 10–20%.
- Innovation in auto-injector technology or biosimilar entry might further impact pricing structures.
- Expected pricing trend: Slight decline or stabilization at USD 200–250 for a two-pack, assuming patent expiry of current formulations and expansion of generics.
Regulatory and Policy Impact
- Recent FDA actions emphasize lowering costs; in 2019, the agency urged manufacturers to develop affordable options (FDA, 2019).
- State legislations enabling easier access will sustain demand but may pressure manufacturers to maintain price competitiveness.
Key Takeaways
- NDC 00143-9005 (EpiPen) remains the dominant product in a growing allergy auto-injector market.
- Pricing peaked in 2016 but has since declined due to increased generic availability and market pressures.
- Current average retail prices for EpiPen and authorized generics stay in the USD 250–300 range for two packs.
- Price projections suggest stabilization with marginal declines as new alternatives penetrate the market.
- Insurance coverage and patient assistance programs significantly influence final consumer costs.
FAQs
1. How does the entry of generics impact the market for NDC 00143-9005?
Generic auto-injectors, like authorized generics, exert downward pressure on prices, reducing brand premiums. Their presence increases market competition, leading to more affordable options for consumers.
2. What factors could cause prices of NDC 00143-9005 to increase?
Regulatory changes limiting competition, supply chain disruptions, or increased demand without proportional supply growth could cause prices to rise.
3. Are newer formulations of epinephrine auto-injectors likely to replace NDC 00143-9005?
Yes. Innovations like smaller devices or alternative delivery mechanisms could displace existing formulations if they offer improved ease of use or cost advantage.
4. How do insurance policies influence the actual out-of-pocket costs for patients?
Insurance coverage, copay assistance, and manufacturer coupons significantly reduce patient expenses, sometimes bringing prices close to USD 0.
5. What is the outlook for price competition in the next five years?
Expect continued price stabilization or marginal decline as generics and biosimilars expand, with ongoing regulatory and market efforts to reduce costs.
References
- American College of Allergy, Asthma & Immunology. (2021). Food allergy statistics.
- FDA. (2019). Guidance on access to epinephrine auto-injectors.
- Grand View Research. (2022). Allergy immunotherapy market analysis.
- MarketsandMarkets. (2022). Auto-injector devices market report.
